Mostrar el registro sencillo del ítem

dc.contributor.authorTena Garitaonaindia, Mireia 
dc.contributor.authorArredondo Amador, María
dc.contributor.authorMascaraque Molina, Cristina 
dc.contributor.authorMartínez Augustín, María Olga 
dc.contributor.authorSánchez De Medina López-Huertas, Fermín 
dc.date.accessioned2022-05-13T10:40:10Z
dc.date.available2022-05-13T10:40:10Z
dc.date.issued2022-01-04
dc.identifier.citationMireia Tena-Garitaonaindia... [et al.]. Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models, Pharmacological Research, Volume 177, 2022, 106056, ISSN 1043-6618, [https://doi.org/10.1016/j.phrs.2022.106056]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/74824
dc.descriptionThis work was supported by the "Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd)", belonging to Instituto de Salud Carlos III, Spain, and grants from: Ministry of Economy and Competitivity, partly with Fondo Europeo de Desarrollo Regional FEDER funds [SAF2017-88457-R, AGL2017-85270-R]; "Junta de Andalucia", Spain [CTS235, CTS164]; "Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III", Spain (PI19/00819), co-funded by European Regional Development Fund/European Social Fund, "Investing in your future"; "Junta de Castilla y Leon" (SA074P20),Spain; "Fundacio Marato TV3'' (201916-31), Spain; AECC Scientific Foundation (2017/2020), Spain; and "Centro Internacional sobre el Envejecimiento" (OLD-HEPAMARKER, 0348_CIE_6_E), Spain. MAA and MTG were supported by fellowships from the Ministry of Education. MA was supported by a postdoctoral contract with the CIBERehd. Funding for open access charge: Universidad de Granada/CBUA.es_ES
dc.description.abstractGlucocorticoids (GCs) are widely used drugs for their anti-inflammatory and immunosuppressant effects, but they are associated with multiple adverse effects. Despite their frequent oral administration, relatively little attention has been paid to the effects of GCs on intestinal barrier function. In this review, we present a summary of the published studies on this matter carried out in animal models and cultured cells. In cultured intestinal epithelial cells, GCs have variable effects in basal conditions and generally enhance barrier function in the presence of inflammatory cytokines such as tumor necrosis factor (TNF). In turn, in rodents and other animals, GCs have been shown to weaken barrier function, with increased permeability and lower production of IgA, which may account for some features observed in stress models. When given to animals with experimental colitis, barrier function may be debilitated or strengthened, despite a positive anti-inflammatory activity. In sepsis models, GCs have a barrier-enhancing effect. These effects are probably related to the inhibition of epithelial cell proliferation and wound healing, modulation of the microbiota and mucus production, and interference with the mucosal immune system. The available information on underlying mechanisms is described and discussed.es_ES
dc.description.sponsorship"Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spaines_ES
dc.description.sponsorshipMinistry of Economy and Competitivityes_ES
dc.description.sponsorshipEuropean Commission SAF2017-88457-R AGL2017-85270-Res_ES
dc.description.sponsorshipJunta de Andalucia European Commission CTS235 CTS164es_ES
dc.description.sponsorshipInstituto de Salud Carlos III PI19/00819es_ES
dc.description.sponsorshipEuropean Regional Development Fund/European Social Fund, "Investing in your future"es_ES
dc.description.sponsorshipJunta de Castilla y Leon SA074P20es_ES
dc.description.sponsorshipFundacio Marato TV3, Spain 201916-31es_ES
dc.description.sponsorshipAECC Scientific Foundation, Spaines_ES
dc.description.sponsorship"Centro Internacional sobre el Envejecimiento" (OLD-HEPAMARKER), Spain 0348_CIE_6_Ees_ES
dc.description.sponsorshipMinistry of Educationes_ES
dc.description.sponsorshipCIBERehdes_ES
dc.description.sponsorshipUniversidad de Granada/CBUAes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectGlucocorticoid es_ES
dc.subjectIntestinal barrier functiones_ES
dc.subjectIgAes_ES
dc.subjectColitis es_ES
dc.subjectStress es_ES
dc.titleModulation of intestinal barrier function by glucocorticoids: Lessons from preclinical modelses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.phrs.2022.106056
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España